Advertisement
Screener

Citius Pharmaceuticals, Inc. (CTXR) Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements

1.7 / 5 stars · 18/54 Roast Me

Citius Pharmaceuticals, Inc. Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements

Citius Pharmaceuticals, Inc. (CTXR) reported Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements of 201.33 thousand shares for the 6-month period ending 2020-03-31, per its 10-Q filed 2020-05-14.

Discontinued › Income Statement › Earnings Per Share

us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements · last filed 2020-05-14

  • Citius Pharmaceuticals, Inc. incremental common shares attributable to dilutive effect of equity unit purchase agreements for the quarter ending 2019-12-31 was 201.33K shares, a 0.00% change year-over-year.
  • Citius Pharmaceuticals, Inc. incremental common shares attributable to dilutive effect of equity unit purchase agreements for the quarter ending 2018-12-31 was 201.33K shares, a 0.00% change year-over-year.
  • Citius Pharmaceuticals, Inc. incremental common shares attributable to dilutive effect of equity unit purchase agreements for the quarter ending 2017-12-31 was 201.33K shares.
  • Citius Pharmaceuticals, Inc. incremental common shares attributable to dilutive effect of equity unit purchase agreements for fiscal 2019 was 201.33K shares, a 0.00% change from fiscal 2018.
  • Citius Pharmaceuticals, Inc. incremental common shares attributable to dilutive effect of equity unit purchase agreements for fiscal 2018 was 201.33K shares.
Period endIncremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements 3 monthIncremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements 6 monthIncremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements 9 monthIncremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements 12 month
2020-03-31201.33K shares
10-Q · filed 2020-05-14
2019-12-31201.33K shares
10-Q · filed 2020-02-13
2019-09-30201.33K shares
10-K · filed 2019-12-16
2019-06-30201.33K shares
10-Q · filed 2019-08-14
2019-03-31201.33K shares
10-Q · filed 2019-05-15
2018-12-31201.33K shares
10-Q · filed 2019-02-14
2018-09-30201.33K shares
10-K · filed 2018-12-11
2018-06-30201.33K shares
10-Q · filed 2018-08-14
2018-03-31201.33K shares
10-Q · filed 2018-05-11
2017-12-31201.33K shares
10-Q · filed 2018-02-14
2017-09-30201.33K shares
10-Q · filed 2018-08-14
2017-06-30201.33K shares
10-Q · filed 2017-08-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
Korsana Biosciences, Inc. (CYCN)United States$0.016B
Lantern Pharma Inc. (LTRN)United States$0.015B-2.87
Anebulo Pharmaceuticals, Inc. (ANEB)United States$0.015B
ACTUATE THERAPEUTICS, INC. (ACTU)United States$0.015B
Pasithea Therapeutics Corp. (KTTA)United States$0.017B-0.81
Tvardi Therapeutics, Inc. (TVRD)United States$0.014B
Vyome Holdings, Inc (HIND)United States$0.014B-1.38
Allarity Therapeutics, Inc. (ALLR)United States$0.017B-1.66
BullFrog AI Holdings, Inc. (BFRG)United States$0.014B
PALATIN TECHNOLOGIES INC (PTN)United States$0.017B-5.36